FDA Warning Letters, BIMO Computerized Systems and 21 CFR 312.62 Records in 2026: What Clinical Trial Data Integrity, Part 11 and eTMF Inspections Actually Cite

TL;DR

Takeaway: The public FDA file that quality and data-management leads are told to mine for “computerized-system warning letters” cites investigator records and protocol execution. It does not rank EDC or eTMF products.

Three computed facts fix the scale of that error.

FDA’s posted warning-letter index in this snapshot holds 3,643 letters. Scan every corresponding HTML body for computerized-system, electronic-records, data-integrity, Part 11, EDC, TMF and 21 CFR 312 language, and 203 letters match any of those patterns. Part 11 matches 4. EDC matches 5. Trial master file matches 1. The same index’s top exact subject is a Tobacco Control Act string (1,186). A CGMP subject-bucket covers 1,002. Exact subject “Clinical Investigator” is 33. Warning letters — EClinCloud analysis, accessed August 2026 [1].

The Form 483 observation file that actually talks about clinical investigations is the BIMO workbook, not the warning-letter keyword hit. On 2,264 dedicated BIMO rows, citation frequency sums — counts of how often a regulation was cited, not a rate of inspections — put 21 CFR 312.60 protocol / Form FDA-1572 compliance at 1,074 and 21 CFR 312.62(b) case-history records at 692. Investigational-product accountability under 312.62(a) sums to 272. Inspection observations — EClinCloud analysis, accessed August 2026 [2][3][4].

Part 11 is a real regulation for electronic records and electronic signatures [5]. It is not the object the public enforcement counts are dominated by. BMIS, the directory people skip, holds 1,841,422 parsed records of clinical investigators, IRBs and CROs named on Forms 1572/1571. It is a denominator of who appears in IND paperwork. It is not a defect rate [6].

The operating decision this paper is for: demand protocol-adherence evidence, 312.62 case histories, and IP accountability from sites and from the systems that store those artifacts. Do not buy a vendor because a spreadsheet was labelled “eClinical warning letters.” A Part 11 SOP wall that cannot produce a contemporaneous case history is the wrong spend.

This is an inspection-object workpaper. It is not a retelling of ICH E6(R3), and it does not promise an inspection outcome.

Open the whole warning-letter index first

Takeaway: Rank the 3,643-letter index by what it actually contains — tobacco, CGMP, foods — before treating a 51-row “eClinical” filename as a market. Exact subject “Clinical Investigator” is 33 letters. The subset is a keyword cut.

A warning letter is an advisory action. FDA says it notifies a firm of violations of regulatory significance and is one of the Agency’s tools for voluntary compliance. It is not a product ranking, not a 483 census, and not a list of EDC vendors [1][7]. The useful first move is to open the whole posted index and name the subject mix. Skipping that step is how a tobacco-heavy file becomes a “clinical data integrity” dashboard.

This snapshot covers issue years 2021–2026. Counts by issue year: 2021 689; 2022 691; 2023 608; 2024 569; 2025 733; 2026 353. The 2026 year is partial through the 31 July 2026 capture. Do not annualize 353 as a full-year run-rate. Warning letters — EClinCloud analysis, accessed August 2026 [1].

Issuing-office strings in the index are messy because FDA does not use one CDER label. The top offices:

The three CDER name variants sum to 970. Tobacco Products alone is 1,204 — one office, a third of the file. CDRH is 220. Warning letters — EClinCloud analysis, accessed August 2026 [1].

Exact subject strings tell the same story from a different column. The top exact subject is Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded at 1,186. Next: CGMP/Finished Pharmaceuticals/Adulterated 339; Foreign Supplier Verification Program (FSVP) 315; Unapproved New Drugs/Misbranded 154; CGMP/QSR/Medical Devices/Adulterated 92. Exact subject Clinical Investigator is 33, tied with a finished-pharmaceuticals misbranding string. One letter in this index has “BIMO” in the subject field. Warning letters — EClinCloud analysis, accessed August 2026 [1].

Subject-buckets — keyword cuts over the subject field, not FDA’s own typology — put CGMP language on 1,002 letters, foods on 369, IDE/PMA on 63, a clinical-investigator family on 45, GLP on 7, bioequivalence on 5, and BIMO on 1. The clinical-investigator bucket (45) is wider than the exact subject “Clinical Investigator” (33) because the bucket also catches strings such as “Clinical Investigator (Sponsor)” and “Clinical Investigator/BIMO.” Neither number is an EDC count. Warning letters — EClinCloud analysis, accessed August 2026 [1].

A packaged 2025–2026 “eClinical” extract in this research set has 51 rows. That filename is a noisy keyword subset, not a finding about the eClinical market. Inside those 51 letters the subjects are still investigator, device-exemption, bioequivalence and GLP objects: Clinical Investigator 13; IDE/PMA adulterated device 11; IDE/PMA 8; in vivo BA/BE clinical 5; GLP 5; then a thin tail of sponsor/investigator and one IRB label. Issuing offices in the subset: CDER 27, CDRH 17, CBER name variants 6, plus one biologics-quality office. Still not EDC brands. Still not a vendor league table. Warning letters — EClinCloud analysis, accessed August 2026 [1].

Read the 51-row file the way you would read a saved search. The search was “eClinical-ish.” The hits were clinical investigators, IDE/PMA letters, BA/BE sites and GLP labs. If a slide deck titles that extract “computerized-system warning letters, 2025–2026,” the title is doing work the rows do not support.

The rest of this paper stays with the full 3,643-letter index, the HTML bodies, the BIMO observation workbook, BMIS, and the guidance titles that actually address electronic records in clinical investigations. The subset is disclosed so it cannot be smuggled back in as a market.

What the HTML actually matches

Takeaway: Across 3,643 warning bodies, 203 letters match any computerized/records pattern. Data integrity (105) and electronic records (96) are mostly CGMP language. Part 11 = 4; EDC = 5; trial master file = 1. Keyword hits are not inspection rates and not vendor counts.

The index subject is a short label. The letter body is where “data integrity,” “Part 11,” “EDC” and “trial master file” would actually appear if this were an eClinical-product file. Every HTML warning in the snapshot was scanned — 3,643 files, matching the 3,643 index rows. 203 letters matched any of a fixed pattern list. That is 5.6% of the index, and it is a string-match count, not a BIMO inspection rate. Warning letters — EClinCloud analysis, accessed August 2026 [1].

A letter may hit several patterns. Summing the pattern column therefore overcounts letters and is useful only as a map of which phrases fire.

Warning letters — EClinCloud analysis, accessed August 2026 [1].

The two largest buckets are the contamination warning. Data integrity on 105 letters and electronic records on 96 letters look, on a slide, like a clinical-systems theme. They are not. FDA’s own Data Integrity and Compliance With Drug CGMP: Questions and Answers (final 13 December 2018) defines data integrity for drug current good manufacturing practice — completeness, consistency and accuracy of CGMP data, with ALCOA as the familiar shorthand — and points at 21 CFR 211/212 manufacturing records, not at investigator case histories [8]. When a finished-pharmaceuticals warning letter says “data integrity” or “electronic records,” it is usually talking about laboratory chromatograms, batch records and audit trails in a plant. Folding those 105 and 96 hits into an EDC dashboard is how manufacturing CGMP becomes a fake clinical ranking.

The clinical-regulation patterns are smaller and more specific. 312.60 appears in 44 letter bodies; 312.62 in 10. Those are investigator-responsibility and investigator-recordkeeping cites [2][3]. They are the HTML echo of the BIMO frequency story in the next section. They are still letter-body string matches, not a count of unique investigations.

Computerized system matches 18 letters; electronic system 15; source data 12; ALCOA 11. ALCOA in a CGMP letter is not ALCOA in an eCRF. The word is shared. The predicate rule is not.

Then the product-shaped words collapse. EDC matches 5 letters. Part 11 matches 4. Trial master file matches 1. Those are the numbers teams cite when they want a vendor list. They are also the numbers that show why this index will not give them one. Five EDC string hits in 3,643 letters is not “EDC is never inspected.” It is “this public warning-letter corpus does not name EDC products as its enforcement object.” One TMF string hit is not “TMF does not matter.” It is “TMF is almost invisible as a warning-letter keyword.” The FAQ returns to that distinction.

NIH RePORTER is a useful contrast for the same class of error, from a different agency file. A 31-phrase eClinical query set in this research retrieves 4,876 unique projects. The phrase “electronic data capture” retrieves 1,023 projects. “trial master file” retrieves 10. “clinical trial management system” retrieves 160. “wearable sensor” retrieves 2,049. Title/abstract keyword hits move with the queries for EDC (698), CTMS (131) and eTMF (10). NIH RePORTER — EClinCloud analysis, accessed August 2026 [9].

Wearable-sensor volume in that cut is the query-boundary warning. The 31 phrases were chosen to look like eClinical operations. One of them is a device-and-physiology phrase that floods the corpus. TMF almost does not appear. That is not a finding that trial master files are unused in NIH-funded work. It is a finding that this query list does not surface TMF. The 51-row warning-letter subset and the NIH phrase list fail in the same way: the filename is not the market.

What the HTML pass supports, after the CGMP contamination is disclosed:

• Do not rank eClinical vendors from this warning-letter index.
• If you report “data integrity warning letters,” split manufacturing CGMP from clinical-investigator letters, or you are counting plants.
• Part 11 = 4 and EDC = 5 are real, small string counts. They are not a Part 11 enforcement vacuum and not an EDC safety certificate.
• The clinical objects that do appear — 312.60 in 44 bodies, 312.62 in 10 — point at investigator protocol and records, which is where the BIMO workbook is much louder.

BIMO observation frequencies

Takeaway: Among 33,723 all-program observation rows, the dedicated BIMO file is 2,264 rows. Frequency sums concentrate on 312.60 protocol/FD-1572 (1,074) and 312.62(b) case histories (692), not on product names. 1,222 blank citation rows are a sheet artifact. Frequencies are citation counts, not “% of inspections.”

FDA’s public inspection-observations spreadsheets summarize areas of regulation cited on system-generated Form FDA 483s, by fiscal year and by program-area tab. They are not a comprehensive listing of every 483. Some 483s are prepared manually and never enter these tools. Observations are “the area of regulation and the number of times it was cited,” not a denominator of inspections performed [4][10].

The all-program workbook in this snapshot has 33,723 rows. Program-area labels, which FDA does not keep as a single clean partition, are dominated by Foods 13,256, then Drugs 6,676, Devices 4,766, Human Tissue 1,875, Biologics 1,549. A tab labelled BIMO has 1,291 rows; a tab labelled Bioresearch Monitoring has 973. Those two labels are not interchangeable, and adding them does not produce the dedicated BIMO extract. Veterinary and radiological tabs fill most of the rest. Inspection observations — EClinCloud analysis, accessed August 2026 [4].

BIMO is therefore not “most of FDA.” Foods alone is 39% of the all-program rows. The clinical-research 483 story lives in a minority tab, which is why a quality lead who only watches warning-letter RSS feeds will under-see investigator records and over-see tobacco and CGMP.

FDA describes BIMO as a program of on-site inspections, data audits and remote regulatory assessments meant to protect data integrity in applications and the rights of human subjects. The program is shared across FDA’s centers [11][12]. The public observation file is one downstream count of what investigators wrote on 483s in that program. It is not the inspection workplan.

The dedicated BIMO extract used here has 2,264 rows spanning fiscal years 2006–2025. Row counts by fiscal year wander from 161 (2006 and 2009) down to 63 (2021) and sit at 91 in FY2025. Those are rows in a spreadsheet, not inspections completed, and they should not be charted as a BIMO activity time series. Inspection observations — EClinCloud analysis, accessed August 2026 [4].

1,222 of those 2,264 BIMO rows have a blank regulation citation and blank short description. That is 54% of the dedicated file. It is sheet structure and header residue, not 1,222 mysterious “blank citations.” Do not treat a blank row as a cite, and do not drop it into a “most common observation” ranking.

On the rows that do carry a citation, frequency is a citation count. FDA’s own observations page says the spreadsheets report how many times an area of regulation was cited [4]. Dividing a frequency sum by 2,264 rows, or by an unknown inspection count, does not produce a rate. The number to use is the sum.

Top short-description frequency sums in the BIMO file:

Inspection observations — EClinCloud analysis, accessed August 2026 [4].

Those objects are in the Code of Federal Regulations. They are not vendor feature lists.

21 CFR 312.60 assigns the investigator general responsibility for conducting the investigation according to the signed investigator statement, the investigational plan and applicable regulations; for protecting subjects; and for control of the investigational drug, including informed consent under part 50 [3][13]. The signed investigator statement is Form FDA 1572 for drug studies under part 312 [14]. A 1,074 frequency sum on “FD-1572, protocol compliance” is a count of 483 citations about that agreement and that protocol, not a count of “computerized systems failed.”

21 CFR 312.62(b) requires the investigator to prepare and maintain adequate and accurate case histories that record observations and other data pertinent to the investigation on each subject. Case histories include case report forms and supporting data — signed consent forms, medical records, progress notes, hospital charts, nurses’ notes — and must document that informed consent was obtained before participation [2][13]. Frequency sum 692. If the eCRF is incomplete, if source and CRF cannot be reconciled, if consent is missing from the history, that is this object. The workbook’s truncated short description repeats “inadequate.” The regulation does not.

21 CFR 312.62(a) requires adequate records of disposition of the investigational drug, including dates, quantity and use by subjects [2]. Frequency sum 272. Accountability is a drug-reconciliation object. It may be recorded in a pharmacy log, a subject diary, an accountability binder, or an RTSM system. The citation is the record, not the brand of the system.

A second 312.60 line, “informed consent,” sums to 145. Do not merge it with the 1,074 protocol/1572 line. FDA’s workbook kept them as separate short descriptions; this paper does too. 21 CFR 50.27(a) (consent form approved, signed, dated) sums to 189 and lives in the protection-of-subjects part, not in 312 [15].

IRB citations are the other concentrated cluster. 21 CFR 56.115(a)(2) minutes of IRB meetings 250; 56.108(a)(1) initial and continuing review 237; 56.115(a)(5) list of members 139; 56.108(c) members present 120 [16][17]. An IRB minutes gap is not an eTMF product finding. It is an IRB-records finding. If those minutes are filed in an eTMF, the TMF has to be able to produce them. The 483 still names 56.115, not the repository.

21 CFR 312.66 unanticipated problems 140 is the investigator’s IRB-reporting duty [18]. 21 CFR 312.50 sponsor responsibilities 83 is the sponsor analogue: the sponsor is responsible for the investigation, for selecting qualified investigators, and for ensuring the investigation is conducted according to the protocol [19]. Eighty-three is not a small citation object. It is also not the top of this file. The top of this file is the investigator’s protocol and the investigator’s case history.

Row counts of each citation string are a trap. Several of the short descriptions appear on only seven rows each. The frequency on those seven rows is what adds to 1,074 or 692. That is how a fiscal-year workbook is built: one row per year (or per similar slice) carrying a count. Ranking by row count would make every citation look equally rare. Ranking by frequency sum is what FDA’s own description of the file supports [4].

A looser “record-ish” keyword pass over short descriptions finds 121 rows and a frequency sum of 1,280. That pass is a sensitivity check, not a third ranking. It confirms that records language in this workbook is large, and that it is still 312.62-shaped rather than “Part 11”-shaped. Inspection observations — EClinCloud analysis, accessed August 2026 [4].

Put the warning-letter HTML next to these sums without confusing the units. HTML 312.62 string hits in warning letters: 10. BIMO 312.62(b) frequency sum: 692. Different files, different grains, different decades of coverage. The comparison is directional: the 483 workbook talks about case histories at volume; the warning-letter keyword list barely talks about EDC. Neither number is a percentage of clinical investigators.

The action this section changes is the validation and TMF budget. A team that staffs “computerized-system inspection readiness” as a Part 11 poster and an audit-trail screenshot, while 312.62 case histories are incomplete and protocol deviations are not reconstructable, has staffed the wrong object. Demand the 312.60/312.62 artifacts. Then ask whether EDC, eTMF and CTMS can each produce the piece that belongs to that system.

BMIS as the denominator people skip

Takeaway: BMIS holds 1,841,422 parsed records (CI 1,120,176; IRB 668,556; CRO 52,423), with 325 malformed rows quarantined. USA is 1,318,686. The file is a directory of 1572/1571 mentions, not a unique-person census and not a defect rate.

CDER’s Bioresearch Monitoring Information System publishes information on clinical investigators, CROs and IRBs involved in IND studies of human drugs and therapeutic biologics who are listed on a Form FDA 1572 or 1571 submitted to CDER since 1 October 2008. FDA states, in the same paragraph, that BMIS is not intended as a comprehensive list of all CIs, CROs or IRBs in clinical research. Foreign studies not conducted under an IND will not generate a 1572. The public file is updated quarterly [6][12].

This snapshot parses 1,841,422 records. 325 rows failed a width/schema check and remain quarantined. They are not in the type or country counts. Do not silently drop them, and do not add them back as a type. BMIS — EClinCloud analysis, accessed August 2026 [6].

Type codes in the parsed file:

BMIS — EClinCloud analysis, accessed August 2026 [6].

FDA’s own field note is the grain that quality dashboards usually skip: the file contains a separate entry each time a CI, CRO or IRB is identified in a new submission. If a 1572 for the same investigator is submitted on ten INDs, that name appears ten times [6]. 1,120,176 is therefore not 1.12 million unique investigators. It is 1.12 million CI-mention records. Using it as a headcount of US investigators invents a workforce. Using it as a denominator of “how often this kind of entity appears in IND paperwork CDER chose to post” is what the file can bear.

Country is a directory field, not a compliance score. USA 1,318,686 (71.6% of parsed records), then CAN 45,484, DEU 29,479, GBR 29,092, ITA 27,055, ESP 26,701, RUS 24,369, AUS 24,241, FRA 21,813, POL 19,874, JPN 18,247, IND 15,711, BRA 15,360, KOR 14,996, UKR 13,048. BMIS — EClinCloud analysis, accessed August 2026 [6]. FDA’s file layout uses a country code and uses NG for missing state on foreign addresses [6]. A USA-heavy directory is what you expect of an IND/1572-based CDER file. It is not “US sites fail more” and not “non-US sites are uninspected.” Non-IND foreign studies are structurally absent.

Receipt-date in BMIS is a known-noisy field in this extract. FDA documents that 01-JAN-1900 is an invalid date, equivalent to not given [6]. This paper does not trend BMIS by year.

What BMIS is for, in this argument:

• A sense of scale. The BIMO 483 workbook is 2,264 rows. The warning-letter clinical-investigator subject is 33. The directory of 1572/1571 mentions is 1.84 million records. Inspection attention is sparse relative to the paperwork universe. That is how a risk-based BIMO program is supposed to look [11]. It is also why a 33-letter subject slice cannot be a vendor ranking.
• A type mix. CI mentions dominate; IRBs are large; CROs are a 52,423-record minority. Oversight systems that only model “the site” and ignore IRB minutes (56.115) or sponsor/CRO responsibilities (312.50) are not reading the same directory FDA publishes.
• A hard no. BMIS has no deficiency field in this analysis. You cannot divide 692 case-history citations by 1,120,176 CI records and call the result a case-history failure rate. The numerator is 483 citations over many years. The denominator is repeated 1572 mentions. Different objects.

If a slide says “BMIS shows computerized-system risk in CROs,” the slide has assigned a meaning the columns do not have.

The documents that do talk about electronic clinical systems

Takeaway: Part 11 Scope (2003) and the October 2024 electronic-systems Q&A are the clinical computerized-system documents. ICH E6(R3) is a principle pointer, not this paper’s retell. CPG 425.x titles are 1980s manufacturing false friends. The 2018 CGMP data-integrity Q&A is drug manufacturing unless you keep it in that scope.

The enforcement files above are thin on product names. The guidance index is where electronic clinical systems are actually discussed — and even there, a title search is a blunt instrument.

FDA’s public guidance index in this snapshot holds 2,786 rows. A title-bucket for computerized / electronic-records / data-integrity language hits 12 titles. A COA / patient-focused-drug-development bucket hits 10. An eCOA / digital-health-technology bucket hits 1. An ICH-GCP title bucket hits 3. FDA guidance index — EClinCloud analysis, accessed August 2026. Those buckets are search aids. Several of the 12 “computerized” titles are not clinical EDC documents.

False friends first. Compliance Policy Guides CPG Sec. 425.100 through 425.500 are 1987 “Computerized Drug Processing” manufacturing guides: CGMP applicability to hardware and software, vendor responsibility, source code for process-control programs, input/output checking, identification of “persons” on batch records. CPG Sec. 460.400 (1980) is computerized prescription recordkeeping by pharmacies. Dumping those titles into a clinical-systems reading list because the word “computerized” appears is the guidance-index version of counting CGMP “data integrity” warning letters as EDC letters. They stay out of the clinical gates below.

Part 11, Electronic Records; Electronic Signatures — Scope and Application (final 5 September 2003) is the Agency’s current thinking on when part 11 applies. Predicate rules — the underlying record requirements in the Act and in FDA regulations other than part 11 — come first. Under the narrow interpretation FDA describes, part 11 applies when persons choose electronic format in place of paper for records required under predicate rules, or when they rely on the electronic record to perform regulated activities even if a printout exists. The 2003 guidance also describes enforcement discretion on specified part 11 requirements while the Agency’s re-examination of part 11 was underway [5][20]. For a clinical quality lead, the durable point is not a poster of 11.10 clauses. It is: identify the predicate record (312.62 case history, 312.62(a) accountability, 56.115 IRB minutes, consent under part 50), then ask whether the electronic system that holds it is within part 11’s scope as FDA currently applies it.

Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers (final 1 October 2024) is the clinical-specific successor conversation. The guidance page states that it provides information for sponsors, clinical investigators, IRBs, CROs and others on electronic systems, records and signatures in clinical investigations of foods, medical products, tobacco products and new animal drugs, and recommendations under which FDA considers those electronic records and signatures trustworthy, reliable and generally equivalent to paper [21][22]. The PDF is the document to put in the reading pack next to 312.62, not a 1987 CPG. This paper does not paraphrase the Q&A into a fake checklist. It uses it as the Agency’s current clinical-investigations electronic-systems Q&A, issued October 2024, Revision 1 [22].

Data Integrity and Compliance With Drug CGMP: Questions and Answers (13 December 2018) stays in the manufacturing lane unless a sentence is clearly about a clinical site that is also a CGMP facility [8]. ALCOA in that document is CGMP ALCOA. Borrowing it as an EDC policy without naming 312.62 is how a quality system ends up with two ALCOA SOPs and one missing case history.

Data Integrity for In Vivo Bioavailability and Bioequivalence Studies (draft 3 April 2024) is scoped to BA/BE clinical and bioanalytical work supporting INDs, NDAs and ANDAs — a real clinical-data-integrity document, and a different object from either commercial EDC at a multinational site or a finished-dose CGMP lab [23]. The 51-row warning-letter subset’s five BA/BE letters sit closer to this draft than to an eTMF RFP.

Digital Health Technologies for Remote Data Acquisition in Clinical Investigations (final 22 December 2023) is the one title in the eCOA/DHT bucket. It addresses hardware and software used to acquire data remotely from participants [24]. It is not a TMF regulation and not a substitute for 312.62. Adjacent EClinCloud reading on FDA’s COA guidance stays in that lane and is not repeated here.

ICH E6(R3) is cited here as a pointer, not as a second Insight. The Efficacy guidelines page is the official index [25]. The Step 4 consolidated guideline PDF (16 June 2026) is the text [26]. The principle this inspection paper needs from it is narrow: computerized systems should fit the protocol, and records should remain attributable. The operational reading of R3 — risk-based quality management, data governance, digital methods — is already published as EClinCloud’s ICH E6(R3) Insight [27]. This Deep Research article does not retell that page.

What this section changes: the reading pack. Put 312.60, 312.62, the 2003 Part 11 scope guidance, and the 2024 clinical electronic-systems Q&A on the same table. Keep CPG 425.x and the 2018 CGMP Q&A in the manufacturing stack. Use E6(R3) as the GCP principle document, via ICH’s PDF and the existing Insight, not as a third paraphrased SOP.

Demandable gates derived from the citations

Takeaway: The public file supports five demandable artifacts — protocol/1572 evidence, 312.62 case histories, IP accountability, an audit trail if the record is electronic, and a TMF that can produce those objects — not a generic RACI and not an “inspection-ready” claim.

Gates below are compressed from the counts and from the predicate texts already cited. Each one is something a sponsor, CRO, quality lead or data lead can ask a site or a system owner to show, on a named study, without pretending that showing it is a certificate.

1. Protocol-adherence evidence mapped to 312.60 and the signed investigator statement.

BIMO’s largest frequency sum is 312.60 protocol / FD-1572 at 1,074 [3][4][14]. Demand: for this protocol version, the current 1572 (or device equivalent), a deviation log that can be reconstructed without a side spreadsheet, and evidence that changes were either IRB-approved or documented as required to protect subjects. EDC should be able to show the visits, forms and eligibility criteria the protocol required. CTMS should be able to show monitoring and issue-close that touched those deviations. Neither system is a substitute for the investigator’s 312.60 duty.

2. Case-history completeness under 312.62(b).

Frequency sum 692 [2][4]. Demand: for a sample of subjects, the case history — eCRF plus supporting source, consent, and medical-record elements the regulation names — is adequate, accurate and reconstructable. 21 CFR 312.68 requires the investigator, on FDA request, to permit access to copy and verify records required under 312.62 [28]. If the history lives in EDC, EDC is in the inspection path. If the consent and clinic notes live on paper or in a site EHR, those are in the path too. An eTMF that files a blank “CRF complete” checklist without the history behind it has filed a label.

3. Investigational-product accountability under 312.62(a).

Frequency sum 272 [2][4]. Demand: dates, quantities and use by subject, plus disposition of unused supplies. RTSM may hold randomization and kit status. The pharmacy binder may hold receipts. The citation is the investigator’s accountability record. Do not assume EDC captured it because the eCRF has a “drug administered” tick-box.

4. Audit trail and electronic-record controls if the predicate record is electronic.

HTML audit trail matches 44 warning bodies, and the clinical 2024 Q&A plus part 11 are the documents that discuss electronic records in investigations [5][21][22]. Demand: where the case history, consent, or accountability record is electronic, the system can show who did what when, and the sponsor can explain why that system is in part 11 scope under the 2003 narrow reading [20]. This gate is conditional. A paper accountability log does not become a Part 11 finding by sitting next to an EDC. An electronic case history without an attributable trail is the failure mode the Q&A exists to prevent.

5. A TMF that can produce the artifacts above, not a TMF that is merely complete against an index.

Trial master file matched one warning-letter body. That is not permission to ignore TMF. ICH E6 expects the essential records that allow reconstruction of the trial; the 2024 Q&A expects electronic records that FDA can trust [21][26]. Demand: for a named 312.62 request, the eTMF can retrieve the consent, 1572, accountability, correspondence and monitoring documentation that reconstruct that subject’s history and that site’s protocol adherence. An eTMF that is “100% filed” against a zone index but cannot produce those objects is a filing system, not an inspection object.

Keep the systems distinct when you ask:

AI-assisted classification, OCR or filing may speed retrieval. In EClinCloud’s positioning, those outputs remain human-reviewed. They do not replace the investigator’s 312.62 record or the quality lead’s decision that the artifact is the right artifact.

These gates are study-specific asks. They are not a claim that any platform, certification or SOP set makes a site or sponsor inspection-ready. FDA does not sell that outcome, and this paper does not either.

Frequently asked questions

Takeaway: The 51-row subset is a filename; Part 11 is not the top 483 object; BMIS country counts are directory fields; CGMP data integrity is manufacturing unless scoped otherwise; one TMF warning-letter hit does not mean TMF is optional.

Is the 51-row “eClinical” warning-letter file a picture of the EDC/eTMF market?

No. It is a keyword cut of 2025–2026 letters: 51 rows, 13 Clinical Investigator, 19 IDE/PMA, 5 bioequivalence, 5 GLP, plus a thin sponsor/IRB tail. The parent index is 3,643 letters, tobacco- and CGMP-heavy. Use the cut as a saved search. Do not rank vendors from it [1].

If Part 11 only matches four warning letters, can we deprioritize it?

You can deprioritize Part 11 as a warning-letter keyword. You cannot deprioritize the predicate records part 11 may apply to. BIMO frequency sums put 312.60 protocol/1572 at 1,074 and 312.62(b) case histories at 692 [4]. The 2003 scope guidance and the 2024 clinical Q&A still apply to electronic records used in clinical investigations [20][21]. Four HTML hits mean this warning-letter corpus rarely names part 11. They do not mean electronic case histories are unregulated.

Can BIMO frequency sums be turned into “X% of inspections”?

No. FDA’s observations page reports how often an area of regulation was cited on system-generated 483s, not a count of inspections in the denominator [4][10]. 1,222 BIMO rows are blank sheet artifacts (empty citation and short description). Manual 483s are out of the spreadsheet. 1,074 is a citation frequency sum for one short description. Leave it as a count.

What do BMIS country counts mean for inspection risk?

They mean “where the 1572/1571 mention is addressed in this CDER directory.” USA 1,318,686 of 1,841,422 parsed records is the IND paperwork footprint, with a separate entry each time an entity appears on a new submission [6]. Foreign non-IND research is structurally missing. Country is not a 483 rate. 325 malformed rows are quarantined and not in the country table.

Is “data integrity” in FDA warning letters an EDC finding?

Usually not in this index. 105 letter bodies match “data integrity,” and 96 match “electronic records.” The 2018 Q&A those phrases travel with is drug CGMP [8]. Clinical-investigator exact subject is 33 letters; HTML EDC matches are 5. If you need clinical data integrity, start with 312.62 and the 2024 clinical electronic-systems Q&A [2][21]. Use the CGMP Q&A when the facility is a manufacturing facility.

Does one trial-master-file warning letter mean TMF does not matter?

No. It means TMF is almost invisible as a warning-letter string. The reconstructable trial still needs the essential records E6 describes and the case histories 312.62 requires [2][26]. An eTMF is one place those artifacts can live. Absence of a TMF brand in 3,642 of 3,643 letters is not a finding that FDA will not ask for the documents.

Is BMIS a list of problem investigators?

No. BMIS is a transparency directory of CI, IRB and CRO mentions on 1572/1571 submissions to CDER since October 2008. FDA says it is not comprehensive. It has no deficiency flag in this analysis [6][12]. The Clinical Investigator Inspection List and 483s are different objects.

Should we inspect CPG 425.x as clinical computerized-system policy?

No. Those Compliance Policy Guides are 1980s computerized drug processing manufacturing texts. The clinical documents are the 2003 Part 11 scope guidance and the October 2024 electronic-systems Q&A [20][21]. Keep 425.x with CGMP, next to the 2018 manufacturing data-integrity Q&A [8].

Methodology and limitations

Takeaway: Counts are from public FDA files captured in July–August 2026, plus a 31-phrase NIH RePORTER cut. HTML hits are regex. Observation frequencies are citation counts. BMIS is a directory. 2026 warning letters are partial. Recipient firms are not listed.

Warning-letter index and HTML bodies: public FDA Warning Letters, snapshot 31 July 2026; 3,643 index rows and 3,643 HTML files. Issue year 2026 is incomplete. Subject-buckets and HTML patterns are researcher-defined string rules. A letter may match several patterns. CGMP letters inflate “data integrity” and “electronic records.” Analysis by EClinCloud, accessed August 2026 [1].

Inspection observations: public FDA Inspection Observations spreadsheets, snapshot 23 August 2026; 33,723 all-program rows; dedicated BIMO extract 2,264 rows, FY2006–FY2025. Frequency is FDA’s citation count field. Blank citation/short-description rows (1,222) are treated as a sheet artifact. Program-area labels are not a partition. Manual 483s are out of scope by FDA’s own description [4][10].

BMIS: public CDER BMIS download, snapshot 23 August 2026; 1,841,422 parsed; 325 invalid-width rows quarantined. Type and country are directory fields. Repeat 1572 mentions are separate records. Receipt dates were not trended [6].

Guidance titles: FDA guidance index, snapshot 31 July 2026, 2,786 rows; title-buckets are search aids. ICH E6(R3) cited from ICH.org and the June 2026 Step 4 PDF, not from a local copy [25][26].

NIH RePORTER: 31 predefined eClinical phrases, snapshot 23 August 2026, 4,876 unique projects. Phrase retrieval is not adoption and not a vendor census [9].

This article does not name warning-letter recipients. It does not convert observations into inspection rates. It does not treat certification, user counts or trial counts as evidence. It does not claim that following the gates produces a passing inspection.

Conclusion

Takeaway: Choose the inspection object first — investigator records and protocol, not a vendor brand — then require EDC and eTMF to produce 312.62 artifacts. The public file will not do the ranking for you.

Four facts should survive a 60-second skim.

The warning-letter index is the wrong shopping list. 3,643 letters; tobacco 1,186; CGMP bucket 1,002; Clinical Investigator 33; HTML any-pattern 203; Part 11 4; EDC 5; TMF 1. Start from the whole file. Disclose CGMP contamination of “data integrity” (105) and “electronic records” (96). Ignore the 51-row filename as a market [1][8].

The countable clinical theme is 312.60 and 312.62. BIMO frequency sums: protocol/1572 1,074; case histories 692; accountability 272. Foods still dominate the all-program 483 spreadsheet (13,256 of 33,723). BIMO is a minority program-area, and 1,222 blank rows are residue [4].

BMIS is the scale, not the score. 1,841,422 parsed mentions; CI 1,120,176; IRB 668,556; CRO 52,423; 325 quarantined. Repeat 1572s are repeat rows. No defect rate lives in that directory [6].

The electronic-systems documents are known, and they are not 1987 manufacturing CPGs. 2003 Part 11 scope; 1 October 2024 clinical Q&A; ICH E6(R3) as a principle pointer to the existing Insight. Demand protocol evidence, case histories, accountability, an audit trail when the record is electronic, and a TMF that can produce those objects [20][21][27].

EClinCloud publishes EDC, eTMF and CTMS as distinct systems. The only claim this paper needs is the one the CFR already makes: if those systems hold 312.62 artifacts, they have to be able to produce them. AI-assisted steps stay under human review. No inspection outcome is promised. If you want to walk a study’s records against these gates, start with the protocol and the case history, not with a warning-letter vendor tab.

Sources

1. U.S. Food and Drug Administration, Warning Letters — public index and letter HTML. EClinCloud analysis of 3,643 index rows and 3,643 HTML bodies, snapshot 31 July 2026, accessed August 2026.

2. U.S. Government, 21 CFR 312.62 — Investigator recordkeeping and record retention — (a) disposition of drug; (b) case histories; (c) record retention.

3. U.S. Government, 21 CFR 312.60 — General responsibilities of investigators.

4. U.S. Food and Drug Administration, Inspection Observations — spreadsheets of areas of regulation cited on system-generated Form FDA 483s. EClinCloud analysis of the 23 August 2026 extract (33,723 all-program rows; 2,264 dedicated BIMO rows).

5. U.S. Government, 21 CFR Part 11 — Electronic Records; Electronic Signatures.

6. U.S. Food and Drug Administration, Bioresearch Monitoring Information System (BMIS) — CI, CRO and IRB mentions on Forms 1572/1571 received by CDER since 1 October 2008; not a comprehensive list. EClinCloud analysis of the 23 August 2026 download (1,841,422 parsed records; 325 quarantined).

7. U.S. Food and Drug Administration, About Warning and Close-Out Letters.

8. U.S. Food and Drug Administration, Data Integrity and Compliance With Drug CGMP: Questions and Answers, final 13 December 2018 — drug CGMP, not automatically clinical EDC.

9. National Institutes of Health, RePORTER — EClinCloud analysis of a 31-phrase eClinical query set (4,876 unique projects), snapshot 23 August 2026, accessed August 2026.

10. U.S. Food and Drug Administration, FDA Form 483 Frequently Asked Questions.

11. U.S. Food and Drug Administration, Bioresearch Monitoring Program Information.

12. U.S. Food and Drug Administration, Clinical Investigations Compliance & Enforcement — BIMO and BMIS context.

13. U.S. Food and Drug Administration, Federal Regulations for Clinical Investigators — 21 CFR 312.60, 312.61, 312.62.

14. U.S. Food and Drug Administration, Frequently Asked Questions — Statement of Investigator (Form FDA 1572), June 2010.

15. U.S. Government, 21 CFR 50.27 — Documentation of informed consent.

16. U.S. Government, 21 CFR 56.115 — IRB records.

17. U.S. Government, 21 CFR 56.108 — IRB functions and operations.

18. U.S. Government, 21 CFR 312.66 — Assurance of IRB review.

19. U.S. Government, 21 CFR 312.50 — General responsibilities of sponsors.

20. U.S. Food and Drug Administration, Part 11, Electronic Records; Electronic Signatures — Scope and Application, guidance for industry, September 2003.

21. U.S. Food and Drug Administration, Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers, final 1 October 2024.

22. U.S. Food and Drug Administration, Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers (PDF), October 2024, Revision 1.

23. U.S. Food and Drug Administration, Data Integrity for In Vivo Bioavailability and Bioequivalence Studies, draft 3 April 2024.

24. U.S. Food and Drug Administration, Digital Health Technologies for Remote Data Acquisition in Clinical Investigations, December 2023.

25. International Council for Harmonisation, Efficacy guidelines — E6 Good Clinical Practice index.

26. International Council for Harmonisation, ICH E6(R3) Guideline for Good Clinical Practice, Step 4 consolidated guideline, 16 June 2026.

27. EClinCloud, ICH E6(R3): Clinical trials enter the era of risk-driven digital governance, 10 March 2026 — principle pointer only; this paper does not retell that Insight.

28. U.S. Government, 21 CFR 312.68 — Inspection of investigator’s records and reports.